Compare Moderna, Inc. (MRNA) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Rivian Automotive, Inc. — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Rivian Automotive, Inc. trades at $13.96 (market cap $20.75B). The key difference: Moderna, Inc. is far larger — about 3.8× Rivian Automotive, Inc.'s market cap, and Moderna, Inc. is trading nearer its 52-week high, Rivian Automotive, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Rivian Automotive, Inc. for 61 Days on average.
| MRNA | RIVN | |
|---|---|---|
Market Cap | $78.65B | $20.75B |
Volume | 37,373,437 | 26,144,654 |
Sector | Health | Consumer Cyclical |
52-Week High | $203.46 | $22.45 |
52-Week Low | $22.36 | $12.50 |
Typical Hold Time | 59 Days | 61 Days |
Enterprise Value | $74.80B | $20.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
Rivian Automotive (RIVN) trades at $14.33, down slightly by 0.07% on the day, amid a bearish technical outlook but with improving operational trends. The company reported record Q3 2026 deliveries of 19,248 vehicles, beating estimates and reaffirming full-year guidance, though the stock dipped as investors hoped for a forecast upgrade. Financially, revenue growth continues but losses persist, with a net income margin of -54.95% in 2025, while cash burn has moderated from prior years.
The outlook remains challenged by high cash burn and competitive pressures, but cost controls and R2 SUV ramp-up offer a path to profitability. Analyst consensus is cautiously optimistic with a $16.89 price target, though risks include execution delays and EV market volatility. The stock presents a high-risk, high-reward opportunity for investors betting on Rivian's scaling and autonomy initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
